Latest & greatest articles for topiramate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on topiramate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on topiramate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for topiramate

21. Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review [Cochrane Protocol]

Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

22. Topiramate monotherapy for juvenile myoclonic epilepsy. (PubMed)

Topiramate monotherapy for juvenile myoclonic epilepsy. Topiramate is a newer broad-spectrum of antiepileptic drug (AED). Some studies have shown the benefits of topiramate monotherapy in the treatment of juvenile myoclonic epilepsy (JME). However, there are no current systematic reviews to determine the efficacy and tolerability of topiramate monotherapy in people with JME.To determine the efficacy and tolerability of topiramate monotherapy in the treatment of JME.We searched the Cochrane (...) randomized controlled trials (RCTs) investigating topiramate monotherapy versus placebo or other AED treatment for people with JME, with the outcomes of proportion of responders or experiencing adverse events (AEs).Two review authors independently screened the titles and abstracts of identified records, selected studies for inclusion, extracted data, cross-checked the data for accuracy and assessed the methodological quality. We performed no meta-analyses due to the limited available data.We included

2015 Cochrane

23. Adverse effects of galantamine, topiramate and cotrimoxazole

Adverse effects of galantamine, topiramate and cotrimoxazole Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole'', 1 July 2015 {1} {1} {1} | | > > > In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight In the July issue of Prescrire International: adverse effects of galantamine, topiramate and cotrimoxazole FREE DOWNLOAD All in one sample page: from serious skin reactions with Alzheimer's drug galantamine and visual field defects with topiramate to the potentially deadly effects of the antibiotic cotrimoxazole, either alone or when coadministrered with an ACE inhibitor or ARB. Sample page available for free download. Cotrimoxazole + an ACE inhibitor

2015 Prescrire

24. Is immediate-release topiramate an effective treatment for adult obesity?

Is immediate-release topiramate an effective treatment for adult obesity? Is immediate-release topiramate an effective treatment for adult obesity? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Is immediate-release topiramate an effective treatment for adult obesity? View/ Open Date 2014-12 Format Metadata Abstract Q (...) : Is immediate-release topiramate an effective treatment for adult obesity? Evidence-Based Answer: Yes. Topiramate (at daily doses of 64-400 mg) produces an average 5.34 kg of additional weight loss compared with placebo (95% confidence interval [CI], -6.12 to -4.56) in overweight to obese adults for periods of 16 to 60 weeks (strength of recommendation [SOR]: A, meta-analyses of randomized controlled trials [RCTs]). Topiramate increases the chances of losing 5% or more of aseline body weight (BBW

2015 Clinical Inquiries

25. 4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. (Full text)

4-Year Cost Trajectories in Real-World Patients Matched to the Metabolic Profiles of Trial Subjects Before/After Treatment with Phentermine-Topiramate. Our objective was to estimate 4-year healthcare costs associated with the metabolic profile of patients before and after 1 year of treatment with phentermine (15 mg) and topiramate extended-release (92 mg) [phentermine-topiramate ER].Using a medical records database, we created two patient cohorts reflecting metabolic profiles of subjects before (...) and after phentermine-topiramate ER therapy during the 1-year CONQUER trial. We matched database patients with trial subjects by age, sex, body mass index (BMI), and hypertension, glycemic, and triglyceride status. We collected real-world data on emergency department and outpatient visits, hospitalizations, and drug prescriptions over 4 years, linking them to reimbursements to estimate US private insurance costs for post-trial (n = 2295) versus pre-trial intention-to-treat (ITT) patients (n = 2295

2015 Drugs - real world outcomes Controlled trial quality: uncertain

26. Efficacy and safety of topiramate in patients with essential tremor: a systematic review and meta-analysis

Efficacy and safety of topiramate in patients with essential tremor: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2015 PROSPERO

27. Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination

Topiramate + phentermine (Qsiva and other brands): an excessively dangerous appetite-suppressant combination Prescrire IN ENGLISH - Spotlight: Archive ''Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination'', 1 March 2013 {1} {1} {1} | | > > > Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination Spotlight: Archives Every month, the subjects in Prescrire’s Spotlight. 2013 :   (...) |   |  Spotlight Archives Topiramate + phentermine (Qsiva° and other brands): an excessively dangerous appetite-suppressant combination FEATURED REVIEW Overweight and obese patients must not be exposed to the topiramate + phentermine combination. No beneficial impact on clinical complications of obesity has been demonstrated. A portion of the weight lost is regained after treatment withdrawal. And numerous serious adverse effects have already been observed. Full review (4 pages) available

2014 Prescrire

28. Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism (Full text)

Topiramate Treatment for Heavy Drinkers: Moderation by a GRIK1 Polymorphism Topiramate has been shown to reduce drinking and heavy drinking in individuals with alcohol dependence whose goal was to stop drinking. The authors evaluated the efficacy and tolerability of topiramate in heavy drinkers whose treatment goal was to reduce drinking to safe levels.A total of 138 individuals (62.3% men) were randomly assigned to receive 12 weeks of treatment with topiramate (N=67), at a maximal daily dose (...) of 200 mg, or matching placebo (N=71). Both groups received brief counseling to reduce drinking and increase abstinent days. It was hypothesized that topiramate-treated patients would be better able to achieve these goals, and it was predicted that based on prior research, the effects would be moderated by a single nucleotide polymorphism (rs2832407) in GRIK1, encoding the kainate GluK1 receptor subunit.The rate of treatment completion was 84.9% and equal by treatment group. Topiramate treatment

2014 EvidenceUpdates Controlled trial quality: uncertain

29. Topiramate add-on for drug-resistant partial epilepsy. (PubMed)

Topiramate add-on for drug-resistant partial epilepsy. The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed in 1996, when (...) used as an add-on treatment for drug-resistant partial epilepsy. This is an updated version of the original Cochrane review published in Issue 3, 1999.To evaluate the efficacy and safety of topiramate when used as an add-on treatment for people with drug-resistant partial epilepsy.We searched the Cochrane Epilepsy Group Specialised Register (June 2013); the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 5); MEDLINE (1946 to 2013); SCOPUS (1823 to 2013

2014 Cochrane

30. Topiramate

Topiramate USE OF TOPIRAMATE IN PREGNANCY 0344 892 0909 USE OF TOPIRAMATE IN PREGNANCY (Date of issue: December 2014 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Topiramate is an anticonvulsant used either in monotherapy (...) or as adjunctive therapy in the treatment of generalised tonic-clonic seizures, focal seizures with or without secondary generalisation, and seizures associated with Lennox-Gastaut syndrome. Topiramate is also licensed for the prophylaxis of migraine, and in the United States for weight loss. The majority of the available data relates to use of topiramate for the control of maternal epilepsy. Gestational topiramate exposure has been associated with orofacial clefts in the offspring. However, data

2014 UK Teratology Information Service

31. Topiramate for neuropathic pain and fibromyalgia in adults. (PubMed)

Topiramate for neuropathic pain and fibromyalgia in adults. Topiramate is an antiepileptic drug with multiple possible mechanisms of action. Antiepileptic drugs are widely used to treat chronic neuropathic pain (pain due to nerve damage) and fibromyalgia, and many guidelines recommend them.To assess the analgesic efficacy and associated adverse events of topiramate for chronic neuropathic pain and fibromyalgia in adults (aged 18 years and above).On 8 May 2013, we searched the Cochrane (...) ) was in lumbar radiculopathy. Doses of topiramate were titrated up to 200 mg/day or 400 mg/day. All studies had one or more sources of potential major bias, as they either used LOCF imputation or were of small size.No study provided first tier evidence for an efficacy outcome. There was no convincing evidence for efficacy of topiramate at 200 to 400 mg/day over placebo.Eighty-two per cent of participants taking topiramate 200 to 400 mg/day experienced at least one adverse event, as did 71% with placebo

2013 Cochrane

32. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. (PubMed)

Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007.To describe and assess (...) the evidence from controlled trials on the efficacy and tolerability of antiepileptic drugs other than gabapentin, pregabalin, topiramate, and valproate (which are the subjects of separate Cochrane reviews) for preventing migraine attacks in adult patients with episodic migraine.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In-Process (current week, 15 January 2013), and EMBASE (1974 to 15

2013 Cochrane

33. Topiramate for the prophylaxis of episodic migraine in adults. (PubMed)

Topiramate for the prophylaxis of episodic migraine in adults. Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007.To describe and assess the evidence from controlled trials on the efficacy and tolerability (...) of topiramate for preventing migraine attacks in adult patients with episodic migraine.We searched the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In-Process (current week, 15 January 2013), and EMBASE (1974 to 15 January 2013) and handsearched Headache and Cephalalgia through January 2013.Studies were required to be prospective, controlled trials of topiramate taken regularly to prevent the occurrence

2013 Cochrane

34. Trokendi XR (topiramate) Extended-Release Capsules

Trokendi XR (topiramate) Extended-Release Capsules Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Trokendi XR (topiramate) Extended-Release Capsules Company: Supernus Pharmaceuticals, Inc. Application No.: 201635 Approval Date: 8/16/2013 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2013 FDA - Drug Approval Package

35. Qsiva - phentermine / topiramate

Qsiva - phentermine / topiramate 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. 21 February 2013 EMA/CHMP/108692/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Qsiva International non-proprietary name (...) : PHENTERMINE / TOPIRAMATE Procedure No. EMEA/H/C/002350/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Qsiva CHMP assessment report EMA/CHMP/108692/2013 Page 2/91 Table of contents 1. Background information on the procedure 5 1.1. Submission of the dossier 5 1.2. Manufacturers 6 1.3. Steps taken for the assessment of the product 6 2. Scientific discussion 7 2.1. Introduction 7 2.2. Quality aspects 9 2.2.1. Introduction 9 2.2.2. Active

2013 European Medicines Agency - EPARs

36. Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications (PubMed)

Two Center, Randomized Pilot Study of Migraine Prophylaxis Comparing Paradigms Using Pre-Emptive Frovatriptan or Daily Topiramate: Research and Clinical Implications To compare the efficacy and clinical benefit of 2 paradigms of migraine prevention using pre-emptive frovatriptan and daily topiramate. The study compares the paradigms of pre-emptive use of frovatriptan, a drug approved for acute migraine, and the daily use of topiramate, a Federal Drug Administration-approved and -accepted (...) % of migraine attacks during the premonitory phase and treated with their usual medication. Of these, 55 were randomized to either Group A (daily topiramate) or Group B (frovatriptan during premonitory symptoms); 44 completed the study. The treatment period lasted 2 months. The subjects answered the Migraine-Specific Quality of Life Questionnaire at randomization, and at Weeks 4 and 8. The revised Patient Perception of Migraine Questionnaire was answered 24 hours after taking frovatriptan (Group

2012 EvidenceUpdates Controlled trial quality: uncertain

37. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials

Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

38. Qsymia (phentermine and topiramate extended-release)

Qsymia (phentermine and topiramate extended-release) Drug Approval Package: Qsymia (phentermine and topiramate extended-release) NDA #22580Orig1s000 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Qsymia (phentermine and topiramate extended-release) Capsules CIV Company: Vivus, Inc. Application No.: 22580Orig1s000 Approval Date: 07/17/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF

2012 FDA - Drug Approval Package

39. Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors

Randomised controlled trial: The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors | BMJ Evidence-Based Medicine We (...) of institutional accounts Username * Password * your user name or password? You are here The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity in overweight or obese adults with additional metabolic risk factors Article Text Therapeutics Randomised controlled trial The combination of phentermine and topiramate is an effective adjunct to diet and lifestyle modification for weight loss and measures of comorbidity

2012 Evidence-Based Medicine

40. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. (PubMed)

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. We therefore assessed the efficacy and safety of two doses of phentermine plus topiramate controlled-release combination as an adjunct to diet (...) and lifestyle modification for weight loss and metabolic risk reduction in individuals who were overweight and obese, with two or more risk factors.In this 56-week phase 3 trial, we randomly assigned overweight or obese adults (aged 18-70 years), with a body-mass index of 27-45 kg/m(2) and two or more comorbidities (hypertension, dyslipidaemia, diabetes or prediabetes, or abdominal obesity) to placebo, once-daily phentermine 7·5 mg plus topiramate 46·0 mg, or once-daily phentermine 15·0 mg plus topiramate

2011 Lancet Controlled trial quality: predicted high